vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and WILLAMETTE VALLEY VINEYARDS INC (WVVI). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $11.1M, roughly 1.8× WILLAMETTE VALLEY VINEYARDS INC). WILLAMETTE VALLEY VINEYARDS INC runs the higher net margin — 7.3% vs -177.4%, a 184.7% gap on every dollar of revenue. On growth, WILLAMETTE VALLEY VINEYARDS INC posted the faster year-over-year revenue change (-1.5% vs -11.5%). WILLAMETTE VALLEY VINEYARDS INC produced more free cash flow last quarter ($-532.1K vs $-23.1M). Over the past eight quarters, WILLAMETTE VALLEY VINEYARDS INC's revenue compounded faster (12.3% CAGR vs -12.2%).

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

Willamette Valley Vineyards is an American winery located in Turner, Oregon. Named after Oregon's Willamette Valley, the winery is the leading producer of Willamette Valley-appellated Pinot Noir in Oregon, and also produces Chardonnay and Pinot Gris. In 2016, the winery was the largest producer of Riesling wine in the Willamette Valley.

LAB vs WVVI — Head-to-Head

Bigger by revenue
LAB
LAB
1.8× larger
LAB
$19.6M
$11.1M
WVVI
Growing faster (revenue YoY)
WVVI
WVVI
+10.0% gap
WVVI
-1.5%
-11.5%
LAB
Higher net margin
WVVI
WVVI
184.7% more per $
WVVI
7.3%
-177.4%
LAB
More free cash flow
WVVI
WVVI
$22.6M more FCF
WVVI
$-532.1K
$-23.1M
LAB
Faster 2-yr revenue CAGR
WVVI
WVVI
Annualised
WVVI
12.3%
-12.2%
LAB

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
LAB
LAB
WVVI
WVVI
Revenue
$19.6M
$11.1M
Net Profit
$-34.7M
$811.0K
Gross Margin
48.5%
58.6%
Operating Margin
-168.5%
2.2%
Net Margin
-177.4%
7.3%
Revenue YoY
-11.5%
-1.5%
Net Profit YoY
-28.8%
65.2%
EPS (diluted)
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
WVVI
WVVI
Q4 25
$11.1M
Q3 25
$19.6M
$8.4M
Q2 25
$21.8M
$10.2M
Q1 25
$40.8M
$7.5M
Q4 24
$11.3M
Q3 24
$22.1M
$9.4M
Q2 24
$22.5M
$10.3M
Q1 24
$45.5M
$8.8M
Net Profit
LAB
LAB
WVVI
WVVI
Q4 25
$811.0K
Q3 25
$-34.7M
$-1.1M
Q2 25
$-33.5M
$92.8K
Q1 25
$-26.0M
$-729.0K
Q4 24
$490.9K
Q3 24
$-26.9M
$-282.9K
Q2 24
$-45.7M
$196.0K
Q1 24
$-32.2M
$-521.8K
Gross Margin
LAB
LAB
WVVI
WVVI
Q4 25
58.6%
Q3 25
48.5%
59.9%
Q2 25
48.8%
61.0%
Q1 25
48.4%
63.1%
Q4 24
58.9%
Q3 24
54.9%
62.0%
Q2 24
46.1%
62.6%
Q1 24
53.1%
59.9%
Operating Margin
LAB
LAB
WVVI
WVVI
Q4 25
2.2%
Q3 25
-168.5%
-14.5%
Q2 25
-118.1%
3.9%
Q1 25
-80.8%
-11.5%
Q4 24
6.9%
Q3 24
-120.9%
-1.5%
Q2 24
-134.5%
5.2%
Q1 24
-132.2%
-6.8%
Net Margin
LAB
LAB
WVVI
WVVI
Q4 25
7.3%
Q3 25
-177.4%
-13.1%
Q2 25
-153.7%
0.9%
Q1 25
-63.8%
-9.7%
Q4 24
4.4%
Q3 24
-122.0%
-3.0%
Q2 24
-203.3%
1.9%
Q1 24
-70.6%
-5.9%
EPS (diluted)
LAB
LAB
WVVI
WVVI
Q4 25
Q3 25
$-0.09
Q2 25
$-0.09
Q1 25
$-0.07
Q4 24
Q3 24
$-0.07
Q2 24
$-0.12
Q1 24
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
WVVI
WVVI
Cash + ST InvestmentsLiquidity on hand
$129.4M
$410.9K
Total DebtLower is stronger
$14.0M
Stockholders' EquityBook value
$399.7M
$66.2M
Total Assets
$539.6M
$107.7M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
WVVI
WVVI
Q4 25
$410.9K
Q3 25
$129.4M
$372.6K
Q2 25
$158.6M
$350.6K
Q1 25
$150.9M
$332.9K
Q4 24
$320.9K
Q3 24
$210.6M
$303.2K
Q2 24
$269.8M
$279.8K
Q1 24
$287.1M
$256.5K
Total Debt
LAB
LAB
WVVI
WVVI
Q4 25
$14.0M
Q3 25
Q2 25
Q1 25
Q4 24
$12.9M
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
LAB
LAB
WVVI
WVVI
Q4 25
$66.2M
Q3 25
$399.7M
$67.6M
Q2 25
$424.5M
$68.6M
Q1 25
$454.6M
$68.5M
Q4 24
$69.2M
Q3 24
$489.3M
$71.0M
Q2 24
$510.3M
$71.3M
Q1 24
$577.3M
$71.1M
Total Assets
LAB
LAB
WVVI
WVVI
Q4 25
$107.7M
Q3 25
$539.6M
$107.6M
Q2 25
$557.0M
$106.6M
Q1 25
$579.6M
$108.2M
Q4 24
$109.0M
Q3 24
$681.5M
$107.3M
Q2 24
$708.7M
$106.5M
Q1 24
$777.7M
$106.2M
Debt / Equity
LAB
LAB
WVVI
WVVI
Q4 25
0.21×
Q3 25
Q2 25
Q1 25
Q4 24
0.19×
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
WVVI
WVVI
Operating Cash FlowLast quarter
$-22.2M
$-344.5K
Free Cash FlowOCF − Capex
$-23.1M
$-532.1K
FCF MarginFCF / Revenue
-118.1%
-4.8%
Capex IntensityCapex / Revenue
4.5%
1.7%
Cash ConversionOCF / Net Profit
-0.42×
TTM Free Cash FlowTrailing 4 quarters
$-111.1M
$-2.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
WVVI
WVVI
Q4 25
$-344.5K
Q3 25
$-22.2M
$-1.4M
Q2 25
$-20.7M
$1.3M
Q1 25
$-30.3M
$-1.3M
Q4 24
$-1.1M
Q3 24
$-27.9M
$52.2K
Q2 24
$-39.0M
$800.7K
Q1 24
$-62.5M
$-3.0M
Free Cash Flow
LAB
LAB
WVVI
WVVI
Q4 25
$-532.1K
Q3 25
$-23.1M
$-1.5M
Q2 25
$-22.6M
$1.2M
Q1 25
$-35.3M
$-1.4M
Q4 24
$-1.4M
Q3 24
$-30.1M
$-373.9K
Q2 24
$-41.0M
$45.8K
Q1 24
$-63.3M
$-3.3M
FCF Margin
LAB
LAB
WVVI
WVVI
Q4 25
-4.8%
Q3 25
-118.1%
-18.1%
Q2 25
-103.6%
12.2%
Q1 25
-86.6%
-19.0%
Q4 24
-12.8%
Q3 24
-136.4%
-4.0%
Q2 24
-182.2%
0.4%
Q1 24
-138.9%
-37.7%
Capex Intensity
LAB
LAB
WVVI
WVVI
Q4 25
1.7%
Q3 25
4.5%
1.1%
Q2 25
8.7%
0.7%
Q1 25
12.4%
1.3%
Q4 24
3.2%
Q3 24
10.2%
4.5%
Q2 24
8.6%
7.3%
Q1 24
1.7%
3.5%
Cash Conversion
LAB
LAB
WVVI
WVVI
Q4 25
-0.42×
Q3 25
Q2 25
14.11×
Q1 25
Q4 24
-2.20×
Q3 24
Q2 24
4.09×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

WVVI
WVVI

Direct Sales$5.8M52%
Distributor Sales$5.3M48%

Related Comparisons